AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

Reviewing the amendment protocol of the AstraZeneca's fixed dose combination (FDC) Zibotentan plus Dapagliflozin, the Subject ...

The “somewhat unexpected” finding is likely related to the profound impact on health status from the procedure itself.

He has also received a research grant from AstraZeneca to study the effects of dapagliflozin in inflammatory models. He has previously held stock options in Pfizer and DexCom (minor financial ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has published updated Final Draft Guidance recommending Forxiga (dapagliflozin) as an option to treat chronic ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the results of DERIVE, a Phase 3 study that evaluated the efficacy and safety of FARXIGA ® (dapagliflozin 10 mg), in patients with ...

AMSTERDAM — For patients hospitalized for acute heart failure, initiating treatment with the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) before hospital discharge was safe, it appeared ...

Bristol-Myers Squibb and AstraZeneca announced positive results from a Phase 3 study of dapagliflozin as add-on therapy to metformin for the treatment of type 2 diabetes. This 24-week, randomized ...

Dec 19 (Reuters) - AstraZeneca (AZN.L), opens new tab on Monday won European endorsement for its blockbuster drug, dapagliflozin, as a treatment for all forms of heart failure, the company said.

refused to grant AstraZeneca (“AZ”) an interim injunction to restrain Glenmark from launching in the U.K. a generic version of its type 2 diabetes treatment, Forxiga® (dapagliflozin ...

Please provide your email address to receive an email when new articles are posted on . AstraZeneca announced the FDA has approved its SGLT2 inhibitor dapagliflozin to reduce risk for CV death and ...

Among patients who have heart failure with preserved ejection fraction (HFpEF), 24 weeks of treatment with dapagliflozin (Farxiga; AstraZeneca) reduced pulmonary capillary wedge pressure (PCWP), a ...